First Drug Maker License Suspended Under Vietnam Price Regulations
This article was originally published in PharmAsia News
The Drug Administration of Vietnam took its first action in suspending the license of a foreign drug maker for failing to meet a price-reporting deadline. The DAV suspended temporarily the license of South Korea's Hawon Pharmaceutical for failing to submit price changes for 21 drugs on the Vietnam market. The DAV's director said Hawon was the first foreign company to have its license suspended under the drug-price regulations. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.